AptarGroup, Inc. provides a range of packaging, dispensing, and sealing solutions primarily for the beauty, personal care, home care, prescription drug, consumer health care, injectable, and food and beverage markets. The company operates through three segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma segment provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases in pharmaceutical market; elastomer for injectable primary packaging components; and active packaging products. The Beauty + Home segment primarily sells pumps, closures, aerosol valves, accessories, and sealing solutions to the personal care and home care markets; and pumps and decorative components to the beauty market. The Food + Beverage segment offers dispensing and non-dispensing closures, elastomeric flow control components, spray pumps, and aerosol valves to the food and beverage markets. The company sells its products through own sales force, as well as independent representatives and distributors in Asia, Europe, Latin America, and North America. AptarGroup, Inc. has a strategic partnership with PureCycle Technologies LLC to develop ultra-pure recycled polypropylene into dispensing applications; and a collaboration with Sonmol for developing a digital therapies and services platform targeting respiratory and other diseases. The company was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.
IPO Year:
Exchange: NYSE
Website: aptar.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2024 | $155.00 → $215.00 | Hold → Buy | Jefferies |
| 4/29/2024 | Mkt Perform → Outperform | William Blair | |
| 1/3/2024 | $125.00 → $150.00 | Neutral → Outperform | Robert W. Baird |
| 1/20/2022 | $150.00 → $126.00 | Equal-Weight | Morgan Stanley |
| 12/22/2021 | $162.00 → $156.00 | Overweight | Wells Fargo |
| 12/20/2021 | $148.00 → $145.00 | Buy | Deutsche Bank |
| 11/1/2021 | $158.00 → $148.00 | Buy | Deutsche Bank |
| 9/13/2021 | $150.00 → $135.00 | Neutral | Baird |
| 8/3/2021 | $165.00 → $162.00 | Overweight | Wells Fargo |
| 8/2/2021 | Outperform → Market Perform | William Blair |
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024363414/en/
The Board of Directors of AptarGroup, Inc. (NYSE:ATR) authorized the repurchase of up to $500 million of the Company's common stock. This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. The Board also declared a quarterly cash dividend of $0.45 per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024. Stephan Tanda, President and CEO, commented, "Aptar maintains a balanced approach to capital allocation, focused on returning capital to shareholders, as well as reinvesting in the business through capacity ex
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported solid second quarter results driven by continued growth of the company's proprietary drug delivery systems and margin improvement. Reported sales increased by 2% and core sales, excluding currency and acquisition effects, increased by 3%. Aptar reported net income of $90 million for the quarter, a 9% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725389689/en/Photo: Aptar "Strong sales growth in our Pharma business and broad-based margin expansion helped us achi
Following an increase of almost 8% a year ago AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share, an almost 10% increase from the previous dividend amount, bringing the new annualized dividend to $1.80 per share. The payment date is August 15, 2024, to stockholders of record as of July 25, 2024. Stephan B. Tanda, Aptar President and CEO, commented, "In light of our continued strong performance across all of our key financial metrics, as well as future growth opportunities, the Board of Directors approved an increase in the quarterly dividend. Over the
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong first quarter results driven by continued growth of the company's proprietary drug delivery systems, increased injectables sales and an improving picture for consumer dispensing technologies in North America. Reported sales increased by 6% and core sales, excluding currency and acquisition effects, increased by 5%. Aptar reported net income of $83 million for the quarter, a 52% increase over the prior year. Reported earnings per share increased 50% to $1.23 and adjusted earnings per share increased 31% to $1.26. This press release features multimed
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.41 per share. The payment date is May 16, 2024, to stockholders of record as of April 25, 2024. As previously announced, Aptar will hold a conference call on Friday, April 26, 2024 at 8:00 a.m. Central Time to discuss the Company's first quarter results for 2024. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors page of the website. Abo
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong fourth quarter operational results driven by double-digit growth of the company's proprietary drug delivery systems and strong growth for fragrance dispensing technologies. Reported sales increased by 5% and core sales, excluding currency and acquisition effects, increased by 2%. Aptar reported net income of $62 million for the quarter, a 6% increase over the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240208100452/en/Photo: Aptar "I am pleased to report that we delivered
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.41 per share. The payment date is February 22, 2024, to stockholders of record as of February 1, 2024. As previously announced, Aptar will hold a conference call on Friday, February 9, 2024 at 8:00 a.m. Central Time to discuss the Company's fourth quarter and year-end results for 2023. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investors pag
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced the dates and times of quarterly conference calls for the year. Any updates to these dates or times will be communicated in subsequent press releases. Quarterly Conference Calls Press Release (1) Conference Call (2) 4th Quarter and Annual 2023 Results February 8, 2024 February 9, 2024, at 8:00 a.m. CT 1st Quarter 2024 Results April 25, 2024 April 26, 2024, at 8:00 a.m. CT 2nd Quarter 2024 Results July 25, 2024 July 26, 2024, at 8:00 a.m. CT 3rd Quarter 2024 Results
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong operational performance driven by continued growth of the company's proprietary drug delivery systems. Strong sales from prestige and mass fragrance dispensing devices also contributed positively to the results. Reported sales increased by 7% and core sales, excluding currency and acquisition effects, increased by 2%. Aptar reported net income of $84 million for the quarter, a 55% increase over the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231025463223/en/Photo: Aptar Co
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
3 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
4 - APTARGROUP, INC. (0000896622) (Issuer)
10-Q - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
10-Q - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
11-K - APTARGROUP, INC. (0000896622) (Filer)
SD - APTARGROUP, INC. (0000896622) (Filer)
8-K - APTARGROUP, INC. (0000896622) (Filer)
10-Q - APTARGROUP, INC. (0000896622) (Filer)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
SC 13G/A - APTARGROUP, INC. (0000896622) (Subject)
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported strong third quarter results due to solid operational performance and margin improvement across the company. Results were driven by growth in proprietary drug delivery systems, as well as increased demand for closure technologies. Reported sales and core sales increased by 2%, as currency and acquisition effects did not impact the quarter. Aptar reported net income of $100 million for the quarter, a 19% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241024363414/en/
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that it was awarded a contract from the U.S. Federal Government to advance development of its ActivShield™ technology. This innovative solution sterilizes medical devices and instruments without the need for a power source, making it a versatile solution for numerous environments, including rural areas, military settings and healthcare facilities with limited or no current sterilization capability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241022369874/en/Figure 1: ActivShield™ film ready to be
The Board of Directors of AptarGroup, Inc. (NYSE:ATR) authorized the repurchase of up to $500 million of the Company's common stock. This new authorization replaces all previous authorizations. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. The Board also declared a quarterly cash dividend of $0.45 per share. The payment date is November 14, 2024, to stockholders of record as of October 24, 2024. Stephan Tanda, President and CEO, commented, "Aptar maintains a balanced approach to capital allocation, focused on returning capital to shareholders, as well as reinvesting in the business through capacity ex
N-Sorb leverages company's proven 3-Phase Activ-Polymer™ platform technology to address recent concerns related to N-nitrosamine impurities in pharmaceuticals AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, announced that its N-Sorb nitrosamine mitigation solution has been accepted into the U.S. Food & Drug Administration's (FDA) Emerging Technology Program (ETP), which helps promote the adoption of innovative approaches to pharmaceutical product design and manufacturing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240923964121/en/Aptar's N-Sorb Nitrosa
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Unidose Liquid System (Unidose) is the delivery system approved with neffy® (epinephrine nasal spray), the first and only needle-free treatment approved by the U.S. FDA for the emergency treatment of patients with allergic reactions (Type I), including anaphylaxis. This marks the first regulatory approval worldwide for nasally-delivered epinephrine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240815936474/en/Photo: Aptar's Unidose System for the neffy® 2 mg (epinephrine nasal spray
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Daniel Ackerman has been named Chief Accounting Officer, effective August 1, 2024. "Since joining Aptar over a decade ago, Dan has provided exemplary leadership. He has built a strong team and taken on increasingly challenging responsibilities, most recently helping to lead our renewed focus on cost management," said Stephan B. Tanda President and CEO of Aptar. "Dan has become a trusted advisor, valued for his integrity and demonstrated commitment to Aptar." Ackerman will continue to lead all corporate finance and accounting functions, working cl
Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today reported solid second quarter results driven by continued growth of the company's proprietary drug delivery systems and margin improvement. Reported sales increased by 2% and core sales, excluding currency and acquisition effects, increased by 3%. Aptar reported net income of $90 million for the quarter, a 9% increase from the prior year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725389689/en/Photo: Aptar "Strong sales growth in our Pharma business and broad-based margin expansion helped us achi
Following an increase of almost 8% a year ago AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dosing, dispensing and protection technologies, today declared a quarterly cash dividend of $0.45 per share, an almost 10% increase from the previous dividend amount, bringing the new annualized dividend to $1.80 per share. The payment date is August 15, 2024, to stockholders of record as of July 25, 2024. Stephan B. Tanda, Aptar President and CEO, commented, "In light of our continued strong performance across all of our key financial metrics, as well as future growth opportunities, the Board of Directors approved an increase in the quarterly dividend. Over the
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that it has been named one of the World's Most Sustainable Companies 2024 by TIME. Aptar is ranked 194 out of top 500 global companies evaluated by TIME and its partner Statista. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625841716/en/Aptar is named one of the World's Most Sustainable Companies by TIME (Graphic: Statista) "Aptar is honored to be part of TIME's inaugural list of the World's Most Sustainable companies which reflects our transparent data reporting and continued commitment
AptarGroup's (NYSE:ATR) short percent of float has risen 20.34% since its last report. The company recently reported that it has 414 thousand shares sold short, which is 0.71% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.46 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is
Wells Fargo analyst Gabe Hajde maintains AptarGroup (NYSE:ATR) with a Overweight and raises the price target from $163 to $168.
The increase brings the new annualized dividend to $1.80 per share. The payment date is August 15, 2024, to stockholders of record as of July 25, 2024.
AptarGroup's (NYSE:ATR) short percent of float has fallen 14.86% since its last report. The company recently reported that it has 367 thousand shares sold short, which is 0.63% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.5 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. Short interest is
Wells Fargo analyst Gabe Hajde maintains AptarGroup (NYSE:ATR) with a Overweight and raises the price target from $160 to $163.
William Blair analyst Matt Larew upgrades AptarGroup (NYSE:ATR) from Market Perform to Outperform.
Baird analyst Ghansham Panjabi maintains AptarGroup (NYSE:ATR) with a Outperform and raises the price target from $150 to $170.
AptarGroup (NYSE:ATR) reported quarterly earnings of $1.26 per share which beat the analyst consensus estimate of $1.15 by 9.57 percent. This is a 31.25 percent increase over earnings of $0.96 per share from the same period last year. The company reported quarterly sales of $915.448 million which beat the analyst consensus estimate of $890.329 million by 2.82 percent. This is a 6.44 percent increase over sales of $860.067 million the same period last year.
Wells Fargo analyst Gabe Hajde maintains AptarGroup (NYSE:ATR) with a Overweight and raises the price target from $157 to $160.
Aptar Names Vanessa Kanu, A Finance Veteran with Over 25 Years of Experience, as Next CFO AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Bob Kuhn, Executive Vice President and Chief Financial Officer (CFO) since 2008, has decided to retire at the end of this year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240725873916/en/(Left to right) Bob Kuhn, Executive Vice President and Chief Financial Officer since 2008, has decided to retire at the end of 2024; Vanessa Kanu will become Executive Vice President and CFO on January 1, 2025,
AptarGroup, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905451175/en/Sarah Glickman Joins Aptar's Board of Directors (Photo: Aptar) "We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah's extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Julie Xing has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230220005172/en/Julie Xing Joins Aptar's Board of Directors (Photo: Aptar) With over 20 years of experience in pharmaceutical, medtech, digital health, biotech and diagnosis, Julie's leadership approach focuses on inspiring teams to deliver sustainable growth in challenging markets and healthcare environments. With her solid track record of business transformation in multiple g
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that Matt Trerotola has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005805/en/Matt Trerotola Joins Aptar's Board of Directors (Photo: Aptar) Matt has served as the President and Chief Executive Officer for Enovis Corporation (formerly Colfax), an innovation-driven medical technology company, since 2015. As a highly accomplished leader with over 30 years of experience, he has a distinct focus on accelerating organic growth as well as s
AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions, announced today that Candace Matthews has joined its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210524005808/en/Candace Matthews Joins Aptar Board of Directors Candace is a highly accomplished business leader with over 30 years of experience developing and marketing products for the healthcare, cosmetics, food and beverage industries. Candace currently serves as the Chief Reputation Officer for Amway, overseeing the company's global reputation strategy and brand, along with its
Jefferies upgraded AptarGroup from Hold to Buy and set a new price target of $215.00 from $155.00 previously
William Blair upgraded AptarGroup from Mkt Perform to Outperform
Robert W. Baird upgraded AptarGroup from Neutral to Outperform and set a new price target of $150.00 from $125.00 previously
Morgan Stanley reiterated coverage of AptarGroup with a rating of Equal-Weight and set a new price target of $126.00 from $150.00 previously
Wells Fargo reiterated coverage of AptarGroup with a rating of Overweight and set a new price target of $156.00 from $162.00 previously
Deutsche Bank reiterated coverage of AptarGroup with a rating of Buy and set a new price target of $145.00 from $148.00 previously
Deutsche Bank reiterated coverage of AptarGroup with a rating of Buy and set a new price target of $148.00 from $158.00 previously
Baird reiterated coverage of AptarGroup with a rating of Neutral and set a new price target of $135.00 from $150.00 previously
Wells Fargo reiterated coverage of AptarGroup with a rating of Overweight and set a new price target of $162.00 from $165.00 previously
William Blair downgraded AptarGroup from Outperform to Market Perform